Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Obesity Surgery
Published in: Obesity Surgery 10/2021

01-10-2021 | Obesity | Review

The Role of Positron Emission Tomography in Bariatric Surgery Research: a Review

Authors: Jason Bini, Mathieu Norcross, Maija Cheung, Andrew Duffy

Published in: Obesity Surgery | Issue 10/2021

Login to get access

Abstract

Bariatric surgery, initially understood as restricting or bypassing the amount of food that reaches the stomach to reduce food intake and/or increase malabsorption of food to promote weight loss, is now recognized to also affect incretin signaling in the gut and promote improvements in system-wide metabolism. Positron emission tomography (PET) is an imaging technique whereby patients are injected with picomolar concentrations of radioactive molecules, below the threshold of having physiological effects, to measure spatial distributions of blood flow, metabolism, receptor, and enzyme pharmacology. Recent advances in both whole-body PET imaging and radioligand development will allow for novel research that may help clarify the roles of peripheral and central receptor/enzyme systems in treating obesity with bariatric surgery.

Graphical abstract

Literature
1.
Hales C, Carroll M, Fryar C, et al. Prevalence of obesity and severe obesity among adults: United States, 2017–2018. Hyattsville, MD: Natl Cent Heal Stat; 2020. February:NCHS Data Brief, no 360
2.
Narayan KM, Boyle JP, Thompson TJ, et al. Effect of BMI on lifetime risk for diabetes research design and. Diabetes Care. 2007;30:1562–6.PubMedCrossRef
3.
Secretan BL, Ph D, Scoccianti C, et al. Body fatness and cancer—viewpoint of the IARC Working Group. N Engl J Med. 2016;375:794–8.CrossRef
4.
Gallagher EJ, Leroith D. Hyperinsulinaemia in cancer. Nat Rev Cancer. 2020;20(11):629–44.
5.
Alford S, Patel D, Perakakis N, et al. Obesity as a risk factor for Alzheimer’s disease: weighing the evidence. Obes Rev. 2018;19:269–80.PubMedCrossRef
6.
Sjostrom L. Review of the key results from the Swedish Obese Subjects (SOS) trial—a prospective controlled intervention study of bariatric surgery. J Intern Med. 2013;273:219–34.PubMedCrossRef
7.
8.
Colquitt JL, Pickett K, Loveman E, et al. Surgery for weight loss in adults. Cochrane Database Syst Rev. 2014;8(8):CD003641.
9.
Pareek M, Schauer PR, Kaplan LM, et al. Metabolic surgery: weight loss, diabetes and beyond. J Am Coll Cardiol. 2018;71:670–87.PubMedCrossRef
10.
Gronroos S, Helmio M, Juuti A, et al. Effect of laparoscopic sleeve gastrectomy vs Roux-en-Y gastric bypass on weight loss and quality of life at 7 years in patients with morbid obesity: the SLEEVEPASS randomized clinical trial. JAMA Surg. 2021;156:137–46.PubMedCrossRef
11.
Valk P. In: Bailey D, Townsend D, Maisey M, editors. Positron emission tomography: basic science and clinical practice. 3rd ed: Springer; 2004.
12.
Phelps ME, Huang SC, Hoffman EJ, et al. Tomographic measurement of local cerebral glucose metabolic rate in humans with (F-18)2-fluoro-2-deoxy-D-glucose: validation of method. Ann Neurol. 1979;6:371–88.PubMedCrossRef
13.
Phelps ME. PET: the merging of biology and imaging into molecular imaging. J Nucl Med. 2000;41:661–81.PubMed
14.
Charron M, Beyer T, Bohnen NN, et al. Image analysis in patients with cancer studied with a combined PET and CT scanner. Clin Nucl Med. 2000;25:905–10.PubMedCrossRef
15.
Sokoloff L, Reivich M, Kennedy C, et al. The [14 C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. J Neurochem. 1977;28:897–916.PubMedCrossRef
16.
Sokoloff L. Relation between physiological function and energy metabolism in the central nervous system. J Neurochem. 1977;29:13–26.PubMedCrossRef
17.
Mäkinen J, Hannukainen JC, Karmi A, et al. Obesity-associated intestinal insulin resistance is ameliorated after bariatric surgery. Diabetologia. 2015;58(5):1055–62.PubMedPubMedCentralCrossRef
18.
Kellett GL, Brot-Laroche E. Apical GLUT2: a major pathway of intestinal sugar absorption. Diabetes. 2005;54:3056–62.PubMedCrossRef
19.
Franquet E, Watts G, Kolodny GM, et al. PET-CT reveals increased intestinal glucose uptake after gastric surgery. Surg Obes Relat Dis Elsevier Inc. 2019;15:643–9.CrossRef
20.
Cavin J-B, Couvelard A, Lebtahi R, et al. Differences in alimentary glucose absorption and intestinal disposal of blood glucose following Roux-en-Y gastric bypass vs sleeve gastrectomy. Gastroenterology Elsevier Ltd. 2016;150:454–64.CrossRef
21.
Pahk K, Park S, Kim S, et al. [18F]-Fluorodeoxyglucose positron emission tomography combined with computed tomography imaging with remission of type 2 diabetes after gastric bypass surgery. J Diabetes. 2016;8:162–4.PubMedCrossRef
22.
Saeidi N, Meoli L, Nestroridi E, et al. Reprogramming of intestinal glucose metabolism and glycemic control in rats after gastric bypass. Science. 2013;341(80):406.PubMedPubMedCentralCrossRef
23.
Iozzo P, Gastaldelli A, Järvisalo MJ, et al. 18F-FDG assessment of glucose disposal and production rates during fasting and insulin stimulation: a validation study. J Nucl Med. 2006;47:1016–22.PubMed
24.
Iozzo P, Jarvisalo MJ, Kiss J, et al. Quantification of liver glucose metabolism by positron emission tomography: validation study in pigs. Gastroenterology. 2007;132:531–42.PubMedCrossRef
25.
Immonen H, Hannukainen JC, Iozzo P, et al. Effect of bariatric surgery on liver glucose metabolism in morbidly obese diabetic and non-diabetic patients. J Hepatol European Association for the Study of the Liver. 2014;60:377–83.
26.
Kwon Y, Pahk K, Park S, et al. Metabolic surgery could restore hepatic glucose metabolism: results from F-18 fluorodeoxyglucose positron emission tomography. Obes Surg. 2016;26(1):156–7.
27.
Cho A, Ph D, Kwon IG, et al. Altered systematic glucose utilization after gastrectomy: correlation with weight loss. Surg Obes Relat Dis. 2020;16:900–7.PubMedCrossRef
28.
Liedtke AJ. Alterations of carbohydate and lipid metabolism in the acutely ischemic heart. Prog Cardiovasc Dis. 1981;23:321–36.PubMedCrossRef
29.
Morbelli S, Marini C, Adami GF, et al. Tissue specificity in fasting glucose utilization in slightly obese diabetic patients submitted to bariatric surgery. Obesity. 2013;21:175–81.CrossRef
30.
Hannukainen JC, Lautamaki R, Parkka J, et al. Reversibility of myocardial metabolism and remodeling in morbidly obese patients six months after bariatric surgery. Diabetes Obes Metab. 2018;20(4):963–73.
31.
Huang X, Wu D, Cheng Y, et al. Restoration of myocardial glucose uptake with facilitated myocardial glucose transporter 4 translocation contributes to alleviation of diabetic cardiomyopathy in rats after duodenal- jejunal bypass. J Diabetes Investig. 2019;10:626–38.PubMedCrossRef
32.
Rudd JHF, Myers KS, Bansilal S, et al. (18)Fluorodeoxyglucose positron emission tomography imaging of atherosclerotic plaque inflammation is highly reproducible: implications for atherosclerosis therapy trials. J Am Coll Cardiol. 2007;50:892–6.PubMedCrossRef
33.
Bucerius J, Vijgen GHEJ, Brans B, et al. Impact of bariatric surgery on carotid artery inflammation and the metabolic activity in different adipose tissues. Medicine (Baltimore). 2015;94:1–9.CrossRef
34.
Bucerius J, Mani V, Moncrieff C, et al. Optimizing 18F-FDG PET/CT imaging of vessel wall inflammation: the impact of 18F-FDG circulation time, injected dose, uptake parameters, and fasting blood glucose levels. Eur J Nucl Med Mol Imaging. 2014;41:369–83.PubMedCrossRef
35.
36.
Choe SS, Huh JY, Hwang IJ, et al. Adipose tissue remodeling: its role in energy metabolism and metabolic disorders. Front Endocrinol (Lausanne). 2016;7:1–16.CrossRef
37.
Bartelt A, Heeren J. Adipose tissue browning and metabolic health. Nat Rev Endocrinol Nature Publishing Group. 2014;10:24–36.CrossRef
38.
Virtanen KA, Lönnroth P, Parkkola R, et al. Glucose uptake and perfusion in subcutaneous and visceral adipose tissue during insulin stimulation in nonobese and obese humans. J Clin Endocrinol Metab. 2002;87:3902–10.PubMedCrossRef
39.
Hany TF, Gharehpapagh E, Kamel EM, et al. Brown adipose tissue: a factor to consider in symmetrical tracer uptake in the neck and upper chest region. Eur J Nucl Med. 2002;29:1393–8.CrossRef
40.
Yeung HWD, Grewal RK, Gonen M, et al. Patterns of 18 F-FDG uptake in adipose tissue and muscle: a potential source of. J Nucl Med. 2003;44:1789–97.PubMed
41.
Cohade C, Osman M, Pannu HK, et al. Uptake in supraclavicular area fat (“USA-Fat”). J Nucl Med. 2003;44:170–7.PubMed
42.
Virtanen KA, Lidell ME, Orava J, et al. Functional brown adipose tissue in healthy adults. N Engl J Med. 2009;360:1518–25.PubMedCrossRef
43.
van Marken Lichtenbelt WD, Vanhommerig JW, Smulders NM, et al. Cold-activated brown adipose tissue in healthy men. N Engl J Med. 2009;360:1500–8.PubMedCrossRef
44.
Saito M, Okamatsu-Ogura Y, Matsushita M, et al. High incidence of metabolically active brown adipose tissue in healthy adult humans: effects of cold exposure and adiposity. Diabetes. 2009;58:1526–31.PubMedPubMedCentralCrossRef
45.
Chen KY, Cypess AM, Laughlin MR, et al. Brown adipose reporting criteria in imaging studies (BARCIST 1.0): recommendations for standardized FDG-PET/CT experiments in humans. Cell Metab. 2016;24:210–22.PubMedPubMedCentralCrossRef
46.
Vijgen GHEJ, Bouvy ND, Teule GJJ, et al. Increase in brown adipose tissue activity after weight loss in morbidly obese subjects. J Clin Endocrinol Metab. 2012;97:1229–33.CrossRef
47.
Rachid B, Rodovalho S, Folli F, et al. Distinct regulation of hypothalamic and brown/beige adipose tissue activities in human obesity. Int J Obes Nature Publishing Group. 2015;39:1515–22.CrossRef
48.
Chen Y, Yang J, Nie X, et al. Effects of bariatric surgery on change of brown adipocyte tissue and energy metabolism in obese mice. Obes Surg 2018;28(3):820-830
49.
Hankir M, Bueter M, Gsell W, et al. Increased energy expenditure in gastric bypass rats is not caused by activated brown adipose tissue. Obes Facts. 2012;5:349–58.PubMedCrossRef
50.
Rao RS, Rao V, Kini S. Animal models in bariatric surgery—a review of the surgical techniques and postsurgical physiology. Obes Surg. 2010;20:1293–305.PubMedCrossRef
51.
Rodovalho S, Rachid B, De-lima-junior J, et al. Impairment of body mass reduction-associated activation of brown/beige adipose tissue in patients with type 2 diabetes mellitus. Int J Obes Nature Publishing Group. 2017;41:1662–8.CrossRef
52.
Dadson P, Landini L, Helmiö M, et al. Effect of bariatric surgery on adipose tissue glucose metabolism in different depots in patients with or without type 2 diabetes. Diabetes Care. 2016;39:292–9.PubMedCrossRef
53.
Suchacki KJ, Tavares AAS, Mattiucci D, et al. Bone marrow adipose tissue is a unique adipose subtype with distinct roles in glucose homeostasis. Nat Commun. 2020;11:3097.
54.
Pham TT, Ivaska KK, Hannukainen JC, et al. Human bone marrow adipose tissue is a metabolically active and insulin sensitive distinct fat depot. J Clin Endocrinol Metab. 2020;7:2300–10.CrossRef
55.
Savolainen AM, Karmi A, Immonen HM, et al. Physical activity associates with muscle insulin sensitivity postbariatric surgery. Med Sci Sports Exerc. 2019;51:278–87.PubMedCrossRef
56.
Silverman DHS. Brain 18F-FDG PET in the diagnosis of neurodegenerative dementias: comparison with perfusion SPECT and with clinical evaluations lacking nuclear imaging. J Nucl Med. 2004;45:594–607.PubMed
57.
Makaronidis JM, Batterham RL. The role of imaging in obesity special feature: review article obesity, body weight regulation and the brain: insights from fMRI. Br J Radiol. 2018;91(1089):20170910.
58.
Marques EL, Halpern A, Mancini MC, et al. Metabolism after bariatric surgery. J Clin Endocrinol Metab. 2014;99:2347–52.CrossRef
59.
Hunt KF, Dunn JT, Roux CW, et al. Differences in regional brain responses to food ingestion after Roux-en-Y gastric bypass and the role of gut peptides: a neuroimaging study. Diabetes Care. 2016;39:1787–95.PubMedCrossRef
60.
Rebelos E, Immonen H, Bucci M, et al. Brain glucose uptake is associated with endogenous glucose production in obese subjects before and after bariatric surgery and predicts metabolic outcome at follow-up. Diabetes Obes Metab. 2019;21:218–26.PubMedCrossRef
61.
Thanos PK, Michaelides M, Subrize M, et al. Roux-en-Y gastric bypass alters brain activity in regions that underlie reward and taste perception. PLoS One. 2015;10:1–19.CrossRef
62.
63.
64.
Bruce KD, Zsombok A, Eckel RH, et al. Lipid processing in the brain: a key regulator of systemic metabolism. Front Endocrinol (Lausanne). 2017;8:1–11.CrossRef
65.
Degrado TR, Coenen HH, Stoã G. 14(R,S)-[18F-]fluoro-6-thia-heptadecanoic acid (FTHA): evaluation in mouse of a new probe of myocardial utilization of long chain fatty acids. J Nucl Med. 1991;32:1888–96.PubMed
66.
Honka H, Koffert J, Hannukainen JC, et al. The effects of bariatric surgery on pancreatic lipid metabolism and blood flow. J Clin Endocrinol Metab. 2015;100:2015–23.PubMedCrossRef
67.
Dadson P, Ferrannini E, Landini L, et al. Fatty acid uptake and blood flow in adipose tissue compartments of morbidly obese subjects with or without type 2 diabetes: effects of bariatric surgery. Am J Physiol Metabolism and Endocrinology. 2017;313(2):E175–82.
68.
Dadson P, Hannukainen JC, Din MU, et al. Brown adipose tissue lipid metabolism in morbid obesity: effect of bariatric surgery-induced weight loss. Diabetes Obes Metab. 2018;20:1280–8.PubMedCrossRef
69.
Immonen HM, Hannukainen JC, Kudomi N, et al. Increased liver fatty acid uptake is partly reversed and liver fat content normalized after bariatric surgery. Diabetes Care. 2018;41:368–71.PubMedCrossRef
70.
Lin CH, Kurup S, Herrero P, et al. Myocardial oxygen consumption change predicts left ventricular relaxation improvement in obese humans after weight loss. Obesity. 2011;19:1804–12.PubMedCrossRef
71.
Koffert J, Stahle M, Karlsson H, et al. Morbid obesity and type 2 diabetes alter intestinal fatty acid uptake and blood flow. Diabetes Obes Metab. 2018;20:1384–90.PubMedPubMedCentralCrossRef
72.
Carreau A, Noll C, Blondin DP, et al. Bariatric surgery rapidly decreases cardiac dietary fatty acid partitioning and hepatic insulin resistance through increased intra-abdominal adipose tissue storage and reduced spillover in type 2 diabetes. Diabetes. 2020;69:567–77.PubMedCrossRef
73.
Rebelos E, Iozzo P, Salminen P, et al. Brain free fatty acid uptake is elevated in morbid obesity, and is irreversible 6 months after bariatric surgery: a positron emission tomography study. Diabetes Obes Metab. 2020;22(7):1074–82.
74.
Rowland N, Marshall JF, Antelman SM, et al. Hypothalamic hyperphagia prevented by damage to brain dopamine-containing neurons. Physiol Behav. 1979;22:635–40.PubMedCrossRef
75.
Missale C, Russel Nash S, Robinson SW, et al. Dopamine receptors: from structure to function. Physiol Rev. 1998;78:189–225.PubMedCrossRef
76.
Farde L, Hall H, Ehrin E, et al. Quantitative analysis of D2 dopamie receptor binding in the living human brain by PET. Science. 1986;231(80):258–61.PubMedCrossRef
77.
Seeman P. Antipsychotic drugs, dopamine receptors, and schizophrenia. Clin Neurosci Res. 2001;1:53–60.CrossRef
78.
79.
80.
Steele KE, Prokopowicz GP, Schweitzer MA, et al. Alterations of central dopamine receptors before and after gastric bypass surgery. Obes Surg. 2010;20:369–74.PubMedCrossRef
81.
Bäckman L, Ph D, Ginovart N, et al. Age-related cognitive deficits mediated by changes in the striatal dopamine system. Am J Psychiatry. 2000;157:635–7.PubMedCrossRef
82.
Karrer TM, Josef AK, Mata R, et al. Reduced dopamine receptors and transporters but not synthesis capacity in normal aging adults: a meta-analysis. Neurobiol Aging. 2018;57:36–46.CrossRef
83.
84.
85.
Dunn JP, Cowan RL, Volkow ND, et al. Decreased dopamine type 2 receptor availability after bariatric surgery: preliminary findings. Brain Res Elsevier BV. 2010;1350:123–30.CrossRef
86.
87.
Karlsson HK, Tuulari JJ, Tuominen L, et al. Weight loss after bariatric surgery normalizes brain opioid receptors in morbid obesity. Mol Psychiatry Nature Publishing Group. 2016;21:1057–62.CrossRef
88.
Kessler RM, Zald DH, Ansari MS, et al. Changes in dopamine release and dopamine D2/3 receptor levels with the development of mild obesity. Synapse. 2014;68:317–20.PubMed
89.
Suissa K, Schneeweiss S, Kim DW, et al. Prescribing trends and clinical characteristics of patients starting antiobesity drugs in the U.S. Diabetes Obes Metab. 2021;23(7):1542–51.
90.
Donovan MH, Tecott LH, Horvath TL. Serotonin and the regulation of mammalian energy balance. Front Neurosci. 2013;7:1–15.CrossRef
91.
Haahr ME, Hansen DL, Fisher PM, et al. Central 5-HT neurotransmission modulates weight loss following gastric bypass surgery in obese individuals. J Neurosci. 2015;35:5884–9.PubMedPubMedCentralCrossRef
92.
de Heide LJM, Glaudemans AWJM, Oomen PHN, et al. Functional imaging in hyperinsulinemic. J Clin Endocrinol Metab. 2012;97:963–7.
93.
Eriksson O, Laughlin M, Brom M, et al. In vivo imaging of beta cells with radiotracers: state of the art, prospects and recommendations for development and use. Diabetologia. 2016;59(7):1340–9.
94.
Eriksson O, Långström B, Antoni G. New ways of understanding the complex biology of diabetes. Nucl Med Biol. 2021;92:65–71.
95.
Gosnell BA, Levine AS. Reward systems and food intake: role of opioids. Int J Obes Nature Publishing Group. 2009;33:S54–8.CrossRef
96.
Peciña S, Smith KS. Pharmacology, biochemistry and behavior hedonic and motivational roles of opioids in food reward: implications for overeating disorders. Pharmacol Biochem Behav Elsevier Inc. 2010;97:34–46.CrossRef
97.
98.
Hankir MK, Patt M, Patt JTW, et al. Suppressed fat appetite after Roux-en-Y gastric bypass surgery associates with reduced brain μ-opioid receptor availability in diet-induced obese male rats. Front Neurosci. 2017;10:1–9.CrossRef
99.
Honka H, Koffert J, Kauhanen S, et al. Bariatric surgery enhances splanchnic vascular responses in patients with type 2 diabetes. Diabetes. 2017;66:880–5.PubMedCrossRef
100.
Honka H, Koffert J, Kauhanen S, et al. Liver blood dynamics after bariatric surgery: the effects of mixed-meal test and incretin infusions. Endocr Connect. 2018;7:888–96.PubMedPubMedCentralCrossRef
101.
Krivokapich J, Smith GT, Huang S. 13N ammonia myocardial imaging at rest and with exercise in normal volunteers: quantification of absolute myocardial perfusion with positron emission tomography. Circulation. 1989;80:1328–37.PubMedCrossRef
102.
Quercioli A, Montecucco F, Pataky Z, et al. Vascular medicine improvement in coronary circulatory function in morbidly obese individuals after gastric bypass-induced weight loss: relation to alterations in endocannabinoids and adipocytokines. European Heart Journal. 2013;34(27):2063–73.
103.
Singhal T, Ding YS, Weinzimmer D, et al. Pancreatic beta cell mass PET imaging and quantification with [11C]DTBZ and [18F]FP-(+)-DTBZ in rodent models of diabetes. Mol Imaging Biol. 2011;13:973–84.PubMedCrossRef
104.
Normandin MD, Petersen KF, Ding Y-S, et al. In vivo imaging of endogenous pancreatic-cell mass in healthy and type 1 diabetic subjects using 18F-fluoropropyl-dihydrotetrabenazine and PET. J Nucl Med. 2012;53:908–16.PubMedCrossRef
105.
Naganawa M, Lin S-F, Lim K, et al. Evaluation of pancreatic VMAT2 binding with active and inactive enantiomers of (18)F-FP-DTBZ in baboons. Nucl Med Biol Elsevier BV. 2016;43:743–51.CrossRef
106.
Cline GW, Naganawa M, Chen L, et al. Decreased VMAT2 in the pancreas of humans with type 2 diabetes mellitus measured in vivo by PET imaging. Diabetologia. 2018;61(12):2598–607.
107.
Inabnet WB, Milone L, Harris PE, et al. The utility of [11 C] dihydrotetrabenazine positron emission tomography scanning in assessing β-cell performance after sleeve gastrectomy and duodenal-jejunal bypass. Surgery. 2010;147:303–9.PubMedCrossRef
108.
109.
Cherry SR, Jones T, Karp JS, et al. Total-body PET: maximizing sensitivity to create new opportunities for clinical research and patient care. J Nucl Med. 2018;59:3–12.PubMedPubMedCentralCrossRef
110.
111.
Methlie P, Dankel S, Myhra T, et al. Changes in adipose glucocorticoid metabolism before and after bariatric surgery assessed by direct hormone measurements. Obesity. 2013;21:2495–503.PubMedCrossRef
112.
Woods CP, Corrigan M, Gathercole L, et al. Tissue specific regulation of glucocorticoids in severe obesity and the response to significant weight loss following bariatric surgery (BARICORT). J Clin Endocrinol Metab. 2015;100:1434–44.PubMedCrossRef
113.
Pardina E, Baena-Fustegueras JA, Fort JM, et al. Hepatic and visceral adipose tissue 11βHSD1 expressions are markers of body weight loss after bariatric surgery. Obesity. 2015;23:1856–63.PubMedCrossRef
114.
Baum E, Zhang W, Li S, et al. A novel 18 F-labeled radioligand for positron emission tomography imaging of 11β-hydroxysteroid dehydrogenase (11β-HSD1): synthesis and preliminary evaluation in nonhuman primates. ACS Chem Neurosci. 2019;10:2450–8.PubMedCrossRef
115.
Bhatt S, Nabulsi NB, Li S, et al. First in-human PET study and kinetic evaluation of [ 18 F]AS2471907 for imaging 11β-hydroxysteroid dehydrogenase type 1. J Cereb Blood Flow Metab. 2020;40(4):695–704.
116.
Bini J, Bhatt S, Hillmer A, et al. Body mass index and age effects on brain 11β-hydroxysteroid dehydrogenase type 1: a positron emission tomography study. Mol Imaging Biol. 2020;22:1124–31.PubMedPubMedCentralCrossRef
117.
Hwang JJ, Yeckel CW, Gallezot JD, et al. Imaging human brown adipose tissue under room temperature conditions with 11C-MRB, a selective norepinephrine transporter PET ligand. Metabolism Elsevier BV. 2015;64:747–55.
118.
119.
Bini J, Naganawa M, Nabulsi NB, et al. Evaluation of PET brain radioligands for imaging pancreatic β-cell mass: potential utility of 11C-PHNO. J Nucl Med. 2018;59(8):1249–54.
120.
Bini J, Sanchez-Rangel E, Gallezot J-D, et al. PET imaging of pancreatic dopamine D3/D2 receptor density with 11 C (+)-PHNO in type-1 diabetes mellitus. J Nucl Med. 2020;61(4):570–6.
121.
Velikyan I, Eriksson O. Advances in GLP-1 receptor targeting radiolabeled agent development and prospective of theranostics. Theranostics. 2020;10:437–61.PubMedPubMedCentralCrossRef
122.
Eriksson O, Velikyan I, Haack T, et al. Drug occupancy assessment at the glucose-dependent insulinotropic polypeptide receptor by positron emission tomography. Diabetes. 2021;70:842–53.PubMedCrossRef
Metadata
Title
The Role of Positron Emission Tomography in Bariatric Surgery Research: a Review
Authors
Jason Bini
Mathieu Norcross
Maija Cheung
Andrew Duffy
Publication date
01-10-2021
Publisher
Springer US
Published in
Obesity Surgery / Issue 10/2021
Print ISSN: 0960-8923
Electronic ISSN: 1708-0428
DOI
https://doi.org/10.1007/s11695-021-05576-7

Other articles of this Issue 10/2021

Obesity Surgery 10/2021 Go to the issue

Original Contributions

Evaluation of Resting Energy Expenditure in Subjects with Severe Obesity and Its Evolution After Bariatric Surgery

Original Contributions

Supervised Exercise Immediately After Bariatric Surgery: the Study Protocol of the EFIBAR Randomized Controlled Trial

Original Contributions

The Effect of Antrum Size on Weight Loss, Glucagon-Like Peptide-1 (GLP-1) Levels, and Glycemic Control Following Laparoscopic Sleeve Gastrectomy in Adolescents with Obesity and Type 2 Diabetes

Brief Communication

Gastric Bypass Sensitizes Sympathetic and Thermogenic Activity of Brown Adipose Tissue to Cold Exposure

Original Contributions

Factors Influencing Early Serum Uric Acid Fluctuation After Bariatric Surgery in Patients with Hyperuricemia

Original Contributions

Improvement in Muscle Strength and Metabolic Parameters Despite Muscle Mass Loss in the Initial Six Months After Bariatric Surgery